MaxCyte, Inc. (MXCT): Price and Financial Metrics
MXCT Price/Volume Stats
| Current price | $3.88 | 52-week high | $5.55 |
| Prev. close | $3.94 | 52-week low | $2.45 |
| Day low | $3.82 | Volume | 529,500 |
| Day high | $3.94 | Avg. volume | 637,435 |
| 50-day MA | $4.35 | Dividend yield | N/A |
| 200-day MA | $4.19 | Market Cap | 405.06M |
MXCT Stock Price Chart Interactive Chart >
MaxCyte, Inc. (MXCT) Company Bio
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Latest MXCT News From Around the Web
Below are the latest news stories about MAXCYTE INC that investors may wish to consider to help them evaluate MXCT as an investment opportunity.
Hedge Funds Say These Penny Stocks Are Poised to ExplodeIn this article, we will take a detailed look at hedge funds say these penny stocks are poised to explode. To see more such stocks, click Hedge Funds Say These 5 Penny Stocks are Poised to Explode. Despite common belief, not all penny stocks are inherently risky and suitable only for short-term gains. Some penny stocks […] |
With 74% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big gunsKey Insights Institutions' substantial holdings in MaxCyte implies that they have significant influence over the... |
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023Doug Doerfler, President and CEO, to Retire Effective December 31, 2023; will continue to serve as an advisor to MaxCyte Maher Masoud, EVP, Head of Global Business Development and Chief Counsel, to Succeed Mr. Doerfler as President and CEO, Effective January 1, 2024 MaxCyte is reiterating 2023 expected core business revenue of $28-30 million, and the Company now expects to exceed prior SPL program-related guidance, with revenue of at least $10 million ROCKVILLE, Md., Dec. 11, 2023 (GLOBE NEWSWIR |
Insider Sell Alert: President and CEO Douglas Doerfler Sells 124,450 Shares of MaxCyte Inc (MXCT)MaxCyte Inc (NASDAQ:MXCT), a global cell-based therapies and life sciences company, has recently witnessed a significant insider sell by its President and CEO, Douglas Doerfler. |
Insider Sell Alert: President and CEO Douglas Doerfler Sells 25,550 Shares of MaxCyte Inc (MXCT)MaxCyte Inc (NASDAQ:MXCT), a global cell-based therapies and life sciences company, has recently witnessed a significant insider sell by its President and CEO, Douglas Doerfler. |
MXCT Price Returns
| 1-mo | -13.00% |
| 3-mo | -24.22% |
| 6-mo | 24.36% |
| 1-year | -23.17% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -17.45% |
| 2023 | -13.92% |
| 2022 | -46.42% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...